Current and Emerging CAR T-Cell Therapies for Myeloma
What are the current and emerging CAR T-cell therapies for myeloma? Nurse practitioner Donna Catamero discusses approved CAR T-cell therapies for multiple myeloma, who they’re appropriate for, ongoing research to expand their use, and treatment options if the disease returns after CAR T-cell therapy.
Donna Catamero is a Nurse Practitioner and associate director of the Multiple Myeloma Clinical Research Program at Mount Sinai Hospital in New York City. Learn more about Donna Catamero.
See More From Thrive CAR T-Cell Therapy
Related Resources:
![]() Undergoing CAR T-Cell Therapy? Why Managing Overall Health Is Essential |
![]() |
![]() CAR T-Cell Therapy Support | Questions to Ask About the Process |
Transcript:
Katherine Banwell:
Donna, welcome. Thank you so much for joining us. Would you please introduce yourself and tell us about your role at Mount Sinai?
Donna Catamero:
Sure. I’m Donna Catamero, I’m a nurse practitioner, and I’m the associate director of the Multiple Myeloma Clinical Research Program at Mount Sinai Hospital in New York City.
Katherine Banwell:
Would you tell us about the currently approved CAR T-cell therapies and which myeloma patients they may be right for?
Donna Catamero:
So, currently, we have two products available for patients. The first is idecabtagene vicleucel (Abecma), and it’s approved for patients with relapsed/refractory disease who have received two prior lines of therapy, and this includes exposure to an immunomodulatory agent, so, your lenalidomide (Revlimid), your pomalidomide (Pomalyst), a proteasome inhibitor, and that includes Velcade/Kyprolis, and an anti-CD38 monoclonal antibody, so this is your daratumumab (Darzalex) or isatuximab-irfc (Sarclisa).
The second product we have to offer patients is ciltacabtagene autoleucel (Carvykti), and this is approved for patients a little bit earlier on, so, also relapsed/refractory disease who have received at least one prior line of therapy, and it must have included proteasome inhibitor and an immunomodulatory agent, and they need to be refractory to Revlimid. So, what “refractory” means is they relapsed while taking the Revlimid.
And both these therapies are important for patients, so if patients are inquiring about CAR T therapy, they should ask their providers what product is available for that.
Katherine Banwell:
Let’s talk about research in CAR T-cell therapy. What new options are being studied, and how far along is the research?
Donna Catamero:
So, we’re actually very excited. So, the two products, Abecma and Carvykti, we’re actually looking at them in newly diagnosed myeloma patients, and this is regardless of if patients are eligible for transplant or not, and we’re looking at comparing transplant versus CAR T therapies, so we’re hoping to move CAR T therapies for newly diagnosed – so, first-line therapy – so this is very exciting, and we’re also investigating new products with dual targets.
So, right now, our two approved CAR Ts, they target BCMA, so now we’re looking at CAR Ts that are targeting BCMA and another target – so, GPRC5D or CD19 – so this means that the CAR T is grabbing onto more cells, so, in theory, it would have a higher cell kill.
And then, we’re also investigating CAR Ts that we call off-the-shelf, so, autologous CAR Ts, so, donor CAR Ts, and this is actually exciting for patients who maybe can’t wait for manufacturing of their T cells, and now we can use donor T cells. So, these are earlier on studies, so we’re hoping within the next few years, more options will be available for patients.
Katherine Banwell:
Yeah. What happens if the myeloma comes back after T-cell therapy? What are the treatment options available beyond CAR T?
Donna Catamero:
Earlier on, we were hoping that CAR T would be our cure, but patients are getting very long, durable remissions from their CAR T therapy. We see patients who are five, seven, eight years out from their CAR T therapy, so patients do have a long time in remission, but the myeloma can come back.
And what do we do with these patients? We actually have been very successful managing patients post a CAR T relapse, so we are looking at bispecific antibodies, which were recently approved over the past several years, and we see patients who have had relapses from their CAR T go back into a remission with these bispecific therapies, and again have long, durable remissions. So, we can absolutely manage patients if their myeloma comes back after CAR T therapy.